HUP0400205A2 - Mellékpajzsmirigy-hormon kibocsátás fokozására adható kinazolinszármazékok alkalmazása gyógyászati készítmények előállítására, eljárás a vegyületek előállítására és új kinazolinszármazékok - Google Patents

Mellékpajzsmirigy-hormon kibocsátás fokozására adható kinazolinszármazékok alkalmazása gyógyászati készítmények előállítására, eljárás a vegyületek előállítására és új kinazolinszármazékok

Info

Publication number
HUP0400205A2
HUP0400205A2 HU0400205A HUP0400205A HUP0400205A2 HU P0400205 A2 HUP0400205 A2 HU P0400205A2 HU 0400205 A HU0400205 A HU 0400205A HU P0400205 A HUP0400205 A HU P0400205A HU P0400205 A2 HUP0400205 A2 HU P0400205A2
Authority
HU
Hungary
Prior art keywords
group
compounds
alkyl
optionally substituted
quinazoline derivatives
Prior art date
Application number
HU0400205A
Other languages
English (en)
Inventor
René Beerli
Ruben Alberto Tommasi
Sven Weiler
Leo Widler
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26246197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0400205(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0114701A external-priority patent/GB0114701D0/en
Priority claimed from GB0114702A external-priority patent/GB0114702D0/en
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0400205A2 publication Critical patent/HUP0400205A2/hu
Publication of HUP0400205A3 publication Critical patent/HUP0400205A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/88—Nicotinoylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgyát (I) általános képletű vegyületek és ezekgyógyászatilag megfelelő és leszakítható észtereinek vagy savaddícióssóinak alkalmazása képezi mellékpajzsmirigy-hormon kiválasztásátfokozó gyógyászati készítmények előállítására, ahol a gyógyászatikészítmények adhatók olyan csontállapotok kezelésére és megelőzésére,amelyek fokozott kalcium kiürítéssel vagy felszívódással állnakkapcsolatban, vagy ahol a csontképződés és a csontban akalciumrögzítés kívánatos. Az (I) általános képletben aszubsztituensek jelentése az alábbi: R4 jelentése Y, vagy R4' csoport;Y jelentése O vagy S; R1 jelentése 1-3 szubsztituens, amelyekegymástól függetlenül -OH, -SH, halogén, -NO2, adott esetbenszubsztituáltalkil-, alkoxi-, alkenil-, alkenil-oxi-, alkinil-,alkinil-oxi-, alkanoil-, alkil-szulfonil-, alkil-szulfoxid- vagyaminocsoport közül választott; R2 jelentése H vagy adott esetbenszubsztituált (rövid szénláncú alkil-, aril-, aril-alkil-,cikloalkil-, cikloalkil-alkil- vagy karbonilcsoport); R3 jelentése 1-3szubsztituens, ami halogénatom, adott esetben szubsztituált (alkil-,cikloalkil-, alkoxi- vagy aminocsoport) közül választott; R4'jelentése cianocsoport, halogénatom, azido- (-N=N=N) vagy adottesetben szubsztituált (alkil-, alkoxi-, tioalkoxi-, aril-oxi-, aril-alkoxi- vagy aminocsoport). Az (I) általános képletű vegyületek egyrésze új, a találmány tárgyát képezik az új vegyületek. Ó
HU0400205A 2001-06-15 2002-06-14 Use of quinazoline derivatives which promote the release of parathyroid hormone for preparation of compounds and new quinazoline derivatives HUP0400205A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0114701A GB0114701D0 (en) 2001-06-15 2001-06-15 Organic compounds
GB0114702A GB0114702D0 (en) 2001-06-15 2001-06-15 Organic compounds
PCT/EP2002/006606 WO2002102782A2 (en) 2001-06-15 2002-06-14 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE

Publications (2)

Publication Number Publication Date
HUP0400205A2 true HUP0400205A2 (hu) 2004-07-28
HUP0400205A3 HUP0400205A3 (en) 2004-10-28

Family

ID=26246197

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400205A HUP0400205A3 (en) 2001-06-15 2002-06-14 Use of quinazoline derivatives which promote the release of parathyroid hormone for preparation of compounds and new quinazoline derivatives

Country Status (31)

Country Link
US (1) US8476286B2 (hu)
EP (2) EP1401451B1 (hu)
JP (2) JP4118801B2 (hu)
KR (1) KR100699959B1 (hu)
CN (1) CN1516587A (hu)
AR (1) AR038658A1 (hu)
AT (1) ATE447958T1 (hu)
AU (1) AU2002325242B2 (hu)
BR (1) BR0210920A (hu)
CA (1) CA2449234C (hu)
CO (1) CO5550443A2 (hu)
CY (1) CY1109767T1 (hu)
CZ (1) CZ20033389A3 (hu)
DE (1) DE60234341D1 (hu)
DK (1) DK1401451T3 (hu)
ES (1) ES2336197T3 (hu)
HU (1) HUP0400205A3 (hu)
IL (2) IL159000A0 (hu)
MX (1) MXPA03011626A (hu)
MY (1) MY145325A (hu)
NO (1) NO326384B1 (hu)
NZ (1) NZ529716A (hu)
PE (1) PE20030121A1 (hu)
PL (1) PL364474A1 (hu)
PT (1) PT1401451E (hu)
RU (1) RU2302244C2 (hu)
SI (1) SI1401451T1 (hu)
SK (1) SK287802B6 (hu)
TW (1) TWI330179B (hu)
WO (1) WO2002102782A2 (hu)
ZA (1) ZA200309042B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
AU2007231842B2 (en) * 2002-12-23 2011-04-14 Novartis Ag Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone
CL2004000868A1 (es) * 2003-04-23 2005-01-21 Japan Tobacco Inc Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis.
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
GB0511410D0 (en) * 2005-06-03 2005-07-13 James Black Foundation Benzotrizepinone derivatives
GB0516723D0 (en) * 2005-08-15 2005-09-21 Novartis Ag Organic compounds
GB0610018D0 (en) * 2006-05-19 2006-06-28 James Black Foundation Benzotriazepinone derivatives
KR100974081B1 (ko) * 2008-07-24 2010-08-04 이화여자대학교 산학협력단 착탈식 치아 교정기구
JP5643233B2 (ja) * 2009-02-10 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン
JP5671453B2 (ja) 2009-04-28 2015-02-18 中外製薬株式会社 スピロイミダゾロン誘導体
MX344109B (es) 2011-10-25 2016-12-05 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
PE20151295A1 (es) 2012-12-10 2015-10-10 Chugai Pharmaceutical Co Ltd Derivado de hidantoina
EP3153166B1 (en) 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1313789A (en) 1919-08-19 Puanookai h cu
US1195066A (en) 1916-08-15 Traction whxel
US1353789A (en) * 1920-09-21 Window-venthiator
US1181570A (en) 1911-03-18 1916-05-02 Churchward Internat Steel Company Alloyed steel.
US1046063A (en) * 1911-12-12 1912-12-03 Frederick H Felt Scale.
US1248428A (en) 1917-06-26 1917-11-27 James Ferdinand Groom Roberts Cooking apparatus.
US3305553A (en) * 1965-10-18 1967-02-21 Parke Davis & Co 2-aminoquinazoline derivatives
CH487902A (de) * 1966-08-29 1970-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Chinazolinonen
FR6001M (hu) * 1966-12-02 1968-04-29
BG16442A3 (bg) * 1967-10-30 1972-11-20 Max Denzer Метод за получаване на нови о-изопропиламинобензофенони
DE1935404C3 (de) 1968-07-18 1975-02-13 Sumitomo Chemical Co., Ltd., Osaka (Japan) Verfahren zur Herstellung von Chinazoline nen
US3923803A (en) * 1968-07-18 1975-12-02 Sumitomo Chemical Co 2(1H)-Quinozalinones and process therefor
BG16042A3 (bg) * 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3767797A (en) * 1969-08-02 1973-10-23 Sumitomo Chemical Co Novel quinazolinone derivatives as antiinflammatory and analgesic agents
US3712892A (en) * 1969-08-02 1973-01-23 Sumitomo Chemical Co Quinazolinone derivatives
JPS5118423B1 (hu) 1970-12-08 1976-06-09
JPS5013271B2 (hu) 1971-10-04 1975-05-19
BE790804A (fr) * 1971-11-18 1973-04-30 Sandoz Sa Procede de preparation de derives de la quinazoline
US3812257A (en) * 1972-04-07 1974-05-21 Sumitomo Chemical Co Uricosuric agent
JPS5418269B2 (hu) * 1972-07-20 1979-07-06
JPS555506B2 (hu) * 1972-09-07 1980-02-07
US3997564A (en) 1973-04-13 1976-12-14 Sandoz, Inc. N-(3,4-methylenedioxy-phenyl)ureas
US4067868A (en) 1973-04-17 1978-01-10 Sumitomo Chemical Company, Limited Production of quinazolinone compounds
JPS5046680A (hu) 1973-08-20 1975-04-25
JPS518287A (en) 1974-07-13 1976-01-23 Sumitomo Chemical Co Kinazorinonjudotaioyobi sonoenno seizoho
JPS5125193A (en) * 1974-08-26 1976-03-01 Sumitomo Chemical Co Kinazorinjudotaino biryoteiryoho
JPS5251379A (en) 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5271483A (en) 1975-12-11 1977-06-14 Sumitomo Chem Co Ltd Synthesis of 2(1h)-quinazolinone derivatives
CH625512A5 (hu) 1976-12-13 1981-09-30 Sandoz Ag
US4171441A (en) 1977-09-06 1979-10-16 Sandoz, Inc. Preparation of quinazolin-2(1H)-ones
JPS5795966A (en) 1980-12-04 1982-06-15 Sumitomo Chem Co Ltd Novel 2(1h)-quinazolinone derivative
TW232013B (hu) 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
DE69422450T2 (de) 1993-06-29 2000-06-08 Takeda Chemical Industries Ltd Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
BRPI9509411B8 (pt) 1994-10-21 2021-07-06 Nps Pharma Inc composto modulador de receptor de íon inorgânico e composição farmacêutica
US5773663A (en) 1996-05-01 1998-06-30 American Cyanamid Company Fungicidal methods, compounds and compositions containing benzophenones
DE19524398C1 (de) * 1995-07-04 1996-11-21 Adalbert Gubo Verfahren zum Archivieren von Dokumenten
CN1136547C (zh) 1995-08-22 2004-01-28 松下电器产业株式会社 光盘记录和／或重放装置及设定记录功率及清除功率的方法
DE69633196D1 (de) 1995-10-16 2004-09-23 Fujisawa Pharmaceutical Co Heterocyclische verbindungen als h+-atpasen
CA2190708A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
AU2001293829A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
JP4530552B2 (ja) * 2001-01-29 2010-08-25 富士通セミコンダクター株式会社 半導体装置及びその製造方法
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7776035B2 (en) * 2004-10-08 2010-08-17 Covidien Ag Cool-tip combined electrode introducer

Also Published As

Publication number Publication date
SI1401451T1 (sl) 2010-03-31
PE20030121A1 (es) 2003-04-02
CY1109767T1 (el) 2014-09-10
CA2449234C (en) 2011-02-15
TWI330179B (en) 2010-09-11
WO2002102782A2 (en) 2002-12-27
CO5550443A2 (es) 2005-08-31
DK1401451T3 (da) 2010-03-29
DE60234341D1 (de) 2009-12-24
JP2008214349A (ja) 2008-09-18
NZ529716A (en) 2006-04-28
US8476286B2 (en) 2013-07-02
CA2449234A1 (en) 2002-12-27
AR038658A1 (es) 2005-01-26
IL159000A0 (en) 2004-05-12
PL364474A1 (en) 2004-12-13
MY145325A (en) 2012-01-31
IL159000A (en) 2009-11-18
SK15212003A3 (sk) 2004-08-03
WO2002102782A3 (en) 2003-05-01
EP1401451A2 (en) 2004-03-31
PT1401451E (pt) 2010-02-18
US20040180912A1 (en) 2004-09-16
CN1516587A (zh) 2004-07-28
EP2191832A1 (en) 2010-06-02
KR20040007702A (ko) 2004-01-24
NO326384B1 (no) 2008-11-24
HUP0400205A3 (en) 2004-10-28
RU2003137571A (ru) 2005-05-10
ES2336197T3 (es) 2010-04-09
BR0210920A (pt) 2008-04-08
KR100699959B1 (ko) 2007-03-27
EP1401451B1 (en) 2009-11-11
ATE447958T1 (de) 2009-11-15
NO20035573D0 (no) 2003-12-12
ZA200309042B (en) 2004-05-21
NO20035573L (no) 2004-02-16
RU2302244C2 (ru) 2007-07-10
JP4118801B2 (ja) 2008-07-16
SK287802B6 (sk) 2011-10-04
AU2002325242B2 (en) 2006-11-09
JP2005502605A (ja) 2005-01-27
CZ20033389A3 (cs) 2004-08-18
MXPA03011626A (es) 2004-04-05

Similar Documents

Publication Publication Date Title
HUP0400205A2 (hu) Mellékpajzsmirigy-hormon kibocsátás fokozására adható kinazolinszármazékok alkalmazása gyógyászati készítmények előállítására, eljárás a vegyületek előállítására és új kinazolinszármazékok
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
ATE286501T1 (de) Pyrimidinderivate
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
ZA200104396B (en) Compositions and methods for stimulating gastrointestinal motility.
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
WO2005056524A3 (en) Therapeutic agents useful for treating pain
WO2004026306A3 (en) Pyrazole derivatives as transforming growth factor (tgf) inhibitors
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
DE60205455D1 (de) Naphthyridinderivate
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
NO20052100D0 (no) Raloksifensalt I
EP2292227A3 (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
DE602005017629D1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
BRPI0514380A (pt) amidas de ácido 5- e 6-amnoalquil indol-2-carboxìlico 3-substituìdo e análogos relacionados como inibidores de caseìna quinase i
NO20021337D0 (no) 4-benzylaminoquinolinkonjugater med gallesyre og deres heteroanaloger, fremgangsmåte for deres fremstilling, legemidlersom inneholder disse forbindelser og deres anvendelse
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria
LT2006062A (lt) Elementinės sieros vaistiniai produktai, skirti su glutationo s transferazės fermentu susijusioms ligoms gydyti
HUP0200129A2 (hu) N-(3'4'-dimetoxi-cinnamoil)-antranilsav alkalmazása szívkoszorúér-műtéttel kapcsolatos cardiovascularis események megelőzésére vagy mérséklésére

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees